Sort publications on year

  • Pharmaco - Epidemiology

    Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme

    TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.

    Eur Respir J ; 2020;55(6)

  • Biometry and database analysis

    The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database

    BOURDIN A, FABRY-VENDRAND C, OSTINELLI J, AIT-YAHIA M, DARNAL E, BOUEE S, LAURENDEAU C, BUREAU I, GOURMELEN J, CHOUAID C.

    J Allergy Clin Immunol Pract ; 2019;7(5):1477-1487

  • Pharmaco-Economics

    Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

    HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MÖLKEN M.

    Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456

  • Biometry and database analysis

    An attempt at modeling COPD epidemiological trends in France

    BURGEL PR, LAURENDEAU C, RAHERISON C, FUHRMAN C, ROCHE N.

    Respir Res ; 2018;19(1):130

  • Pharmaco - Epidemiology

    Etude de validation de l’échelle BDI/TDI dans la bronchopneumopathie chronique obstructive

    LAURENDEAU C, PRIBIL C, PEREZ T, ROCHE N, M-C SIMEONI, DETOURNAY B

    Rev Mal Respir ; 26:735-743

  • Pharmaco - Epidemiology

    Prévalence de la bronchopneumopathie chronique obstructive (BPCO) : estimation pour la France

    BENARD E, DETOURNAY B, NEUKIRCH F, PRIBIL C, EL HASNAOUI A

    La Lettre du Pneumologue ; 8(4):158-163

  • Pharmaco - Epidemiology

    The SCOPE Study : Healthcare consumption related to patients with Chronic Obstructive Pulmonary Disease in France

    DETOURNAY B, PRIBIL C, FOURNIER M, HOUSSET B, HUCHON G, HUAS D, GODARD P, VOINET C, CHANAL I, JOURDANNE C, DURAND-ZALESKI I, the SCOPE Group

    Value Health ; 7(2):168-174

  • Pharmaco-Economics

    Costs associated with community acquired pneumonia in France

    GRECE SABA, LUIZ FLAVIO ANDRADE, JACQUES GAILLAT,  PIERRE BONNIN, CHRISTIAN CHIDIAC,  HAJNAL-GABRIELA ILLES,  HENRI LAURICHESSE,  JONATHAN MESSIKA, JEAN-DAMIEN RICARD,  BRUNO DETOURNAY,  PATRICK PETITPRETZ, GERARD DE POUVOURVILLE

    Eur J Health Econom ; 2018;19(4):533-544

  • Pharmaco-Economics

    Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011

    LAURENDEAU C, CHOUAID C, ROCHE N, TERRIOUX P, GOURMELEN J , DETOURNAY B

    Rev Mal Respir ; 2015;32:682-91

  • Pharmaco-Economics

    Le coût de l’asthme en France et les implications économiques de son niveau de contôle

    GADENNE S, PRIBIL C, CHOUAID C, VERGNENEGRE A, DETOURNAY B

    Rev Mal Respir ; 2011;28(4):419-426

  • Pharmaco-Economics

    The association between asthma control, health care costs, and quality of life in France and Spain

    DOZ M, CHOUAID C, COM-RUELLE L, CALVO E, BROSA M, ROBERT J, DECUYPERE L, PRIBIL C, HUERTA A, DETOURNAY B

    BMC Pulm Med ; 2013;22:13-15